Isodiol International Inc. Signs Definitive Agreement to Acquire 100% Of Canadian National Pharma Group Inc.

0 Comments 4 view(s)

VANCOUVER, British Columbia, Feb. 15, 2018 (GLOBE NEWSWIRE) — Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a Definitive Agreement to acquire 100% of Canadian National Pharma Group Inc. (CN Pharma), a pharmaceutical manufacturing company. Isodiol previously announced on Dec. 6th, 2017 the agreement to acquire an initial stake representing 25% equity of CN Pharma. The company is now pleased to purchase the remaining 75% equity and is excited to establish CN Pharma as a wholly owned subsidiary.

Once approved by Health Canada, CN Pharma will be licensed to process and manufacture controlled substances, handle all cannabis and hemp derivatives, import and export oils and isolates, prepare various formulation and mixtures, participate in research or testing activities, and conduct new product and drug development.

“This is a strategic acquisition for Isodiol, and we intend to expand our capacity in Canada in a significant way,” said Marcos Agramont, CEO of Isodiol. “With this new and up and coming facility, Isodiol will be able to refine and isolate the CBD molecule to a pharmaceutical-grade purity of 99.5% + as well other Cannabinoid derivatives.  As a certified Licensed Dealer, Isodiol will continue to establish strategic partnerships and product licensing agreements …

Full story available on Benzinga.com